Patients' Pain Anxiety Levels Vary Depending on the Type of Pain, the Patient's Gender, and Pain Duration

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

Although patients with cancer pain reported lower levels of current pain than did patients with benign or treatmentrelated pain, their pain anxiety levels were higher, Mikki Miner, RN, MS, said in a poster presentation at the 8th World Congress on Pain.

BUFFALO, NY-Although patients with cancer pain reported lowerlevels of current pain than did patients with benign or treatmentrelatedpain, their pain anxiety levels were higher, Mikki Miner, RN,MS, said in a poster presentation at the 8th World Congress onPain.

Ms. Miner and her colleagues at the Roswell Park Cancer Institutesurveyed 283 outpatients on the Pain Management Service--150 withcancer pain, 40 with treatment-related pain, and 93 with chronicbenign pain--using several psychometric scales for pain anxiety.

The cancer pain patients reported lowest present pain and leastpain within 24 hours, but had higher scores on the pain anxietyscales than the other two groups.

Interestingly, of the four domains of the Pain Anxiety SymptomsScale (PASS)--fear, cognitive anxiety, escape avoidance, and somaticanxiety--females had higher levels of fear and cognitive anxietythan did men.

The study also showed a temporal pattern to pain anxiety acrossall three groups: pain anxiety was highest among patients withpain for more than 6 months but less than 1 year.

"Some of these findings are very intuitive," Ms. Minersaid. "After 6 months of pain, you become anxious. Certainly,the cancer patients would have more anxiety, and that did holdup in this study. It also makes perfect sense for the other twogroups: If you were still in pain 6 months after your trauma ortreatment, you would become anxious."

At the end of 1 year if the pain is still present, Ms. Miner speculatedthat pain anxiety levels drop because patients have either developedother coping skills or the anxiety has changed, maybe into depression.This finding could be helpful in the clinical setting, she noted,since pain and depression are treated differently.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content